Lifeboat Foundation

The major mouse testing pogram is organizing a special 1.5 hour long longevity panel with Dr. Alexandra Stolzing, Dr. Aubrey de Grey and other guests in early June. This was one of the rewards for their campaign on Lifespan.io last year.

They are asking the community to suggest questions to ask Dr. Stolzing and Dr. de Grey so head on over there if you would like to ask them something and maybe it will make the show. The show will be broadcast live on Facebook and the dates will be announced shortly.

We hope to lifestream the science panel to facebook in June and will confirm the time and date shortly.

Continue reading “We are currently organizing our Longevity Panel with Alexandra Stolzing, Aubrey de Grey and a number of other guests” »

https://www.youtube.com/watch?v=B-6-T_StYM8

From 2014, a docu focusing on Aubrey and Bill Andrews.

Live forever… or die trying

Continue reading “The Immortalists” »

What are the bottlenecks in developing a rejuvenation biotechnology industry? LEAF takes a look at some of the main problems we are facing in creating that industry.

One of the most frequent questions we get from the general public is when will rejuvenation therapies arrive? Whilst young people can wait for a few more decades, those in middle age are much more concerned. According to statistics, new drug development takes 17 years on average, but the countdown only begins at the moment when the underlying mechanisms are investigated well enough – which cannot be said about the mechanisms of aging.

We have made great progress in understanding aging in the last decade thanks to the march of technology. One solution to an aging process is entering human clinical trials this year: a therapy to remove aged damaged cells to promote tissue repair and reduce chronic inflammation. This is of course fantastic news but progress is still too slow.

Continue reading “Bottlenecks to the Development of Rejuvenation Biotechnology” »

Aubrey de Grey in this new interview with Vox.

We all grow old. We all die.

For Aubrey de Grey, a biogerontologist and chief science officer of the SENS Research Foundation, accepting these truths is, well, not good enough. He decided in his late twenties (he’s currently 54) that he “wanted to make a difference to humanity” and that battling age was the best way to do it. His life’s work is now a struggle against physics and biology, the twin collaborators in bodily decay.

Continue reading “Scientists are waging a war against human aging. But what happens next?” »

Israel’s oldest newspaper Haaretz (in #Hebrew) recently translated and published The New York Times Magazine feature story on my radical science and #transhumanism work in their own Sunday magazine. I can’t find the link in Hebrew yet, but here’s the fun 2-page spread of me atop my #ImmortalityBus. https://www.nytimes.com/2017/02/09/magazine/600-miles-in-a-c…tself.html

New research in multiple mouse types and human cell lines shows senolytics helps mitigate osteoarthritis.

The removal of senescent cells has shown further potential for the treatment of osteoarthritis in this recent publication where the researchers reduce the impact of post injury osteoarthritis by clearing senescent cells[1]. As we have discussed many times in our publications, senescent cells are a key player in the aging process, if you are new to the subject and want to know what senescent cells are here is a quick primer.

What are senescent cells?

Continue reading “Treating Osteoarthritis” »

Creating rejuvenation will probably be quite expensive, but that’s no reason to give up on it. We can pull it off.

The first thing to realise is that, when you wonder how much something will cost, you’re actually wondering how many resources and how many people doing how much work it will take to do that something. That’s all that really matters. The problem is that we have a sucky economic system such that even if we do have more than enough people and resources to do the job, the monetary cost of it could be so high that you can’t get the job done without creating financial problems left and right. This should be a hint that the problem, if it exists, lies in our crappy economic system, not in rejuvenation itself or whatever other thing we may create.

Apart from the obvious fact that other hysterically expensive endeavours (such as space missions) are pulled off despite their costs, we must take into account that desperate circumstances call for desperate measures. We don’t need to tear apart our economic system and replace it with another before we create rejuvenation, and neither would we if faced with another health crisis (such as a pandemic) or a planetary crisis, but we need to get the job done despite its costs and the consequences they may have. We can’t give up on rejuvenation on the grounds that it may be too expensive to create, just like we wouldn’t in the case of an existential risk. Can you imagine that? There’s a huge asteroid on a collision course with Earth, and our only hope is a spectacularly expensive space mission to destroy it before it’s too late. Just who in their right mind would step up and say: ‘Nah, too expensive. Let’s not do it.

You’ve probably heard about billionaires’ Plan B for when the end of the world comes, much of it centering around property in New Zealand. It’s not exactly a bad plan as far as doomsday prepping goes; buy a nice bunker somewhere in Middle Earth and wait out the chaos in luxury on one of two fairly isolated islands. Now, you may have noticed that front and center for such planning is Silicon Valley billionaire and Trump backer Peter Thiel of the pay-to-sue-Gawker-into-oblivion fame to the public at large, and ultra-libertarian venture capitalist with some crazy ideas about the future to the techies who know him. His backing of seasteading and support for Trump just because he got bored with Obama, are but a warmup to what he really has in mind for the future: immortality as a sentient super-AI.

No, you didn’t read that wrong, and no, this is not hyperbole. In fact, yours truly was once invited to an event where Thiel was a featured speaker after a rather public spat with the president of the Singularity Institute. I did not take up the offer because I had to be in class to learn how to build actual AI systems. And for full disclosure, I was invited to join an advisory board for a group of futurists called The Lifeboat Foundation, but like Groucho Marx, I didn’t want to be involved in a club that would accept someone like me as a member, much less as an advisor based on little more than me being a grad student at the time. So Thiel’s involvement with a group of futurists and an occasional computer scientist who thinks we’re on the verge of something a lot like the plot of Transcendence, is extremely well known in tech.

In fact, the belief that at some point, artificial intelligence and the march of technology will create a singularity that will alter humanity forever, has an alarming number of adherents in Silicon Valley. The face of the Singularity today, Ray Kurzweil, works at Google and runs Singularity University where it’s preached thanks to a multimillion commitment from his employer. And the fact that this belief is so popular in the world’s biggest tech hub isn’t all that surprising if we consider its followers. They’re told that their code and the technology they’re developing is changing the world, or they’re devoted followers of popular science news ready for the incredible future promised to us by the glossy magazines and sci-fi movies to arrive. To be told that by 2035 or 2045 we may become immortal through technology is appealing to say the least, and empowering for those who think they can help.

Continue reading “Why Silicon Valley Can’t ‘Disruptively’ Vote Its Way To Digital Immortality” »

The CellAge project hosted last year with Lifespan.io has now joined up with Michael Greve and Kizoo to develop this technology. Community support for the project has helped move the project foward and will hopefully speed up progress as a result.

April 2017, Edinburgh. CellAge Limited (“CellAge”) has raised a seed round backed by Michael Greve´s Kizoo Technology Capital and a group of angel investors.

CellAge, a privately held synthetic biology start-up aiming to develop tools and therapies for age-related diseases, has successfully completed a seed fundraising round. In this round Kizoo Technology Capital and a number of angel investors have joined the effort to develop synthetic promoters which will make senescent cells identification and removal safer and more efficient. To achieve this, CellAge is planning to analyze transcriptional profiles of a wide range of senescent cell types using proprietary algorithm and construct novel promoters from candidate regulatory elements identified in this screen. The joint expertise in senescence, synthetic biology and bioinformatics gives CellAge a unique angle on improving ways how gene therapies could be targeted to senescent cells.